| Similar Articles |
|---|
 |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.   |
The Motley Fool
September 27, 2007
Brian Orelli |
Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note. |
The Motley Fool
November 25, 2009
Brian Orelli |
Novartis Didn't Know JAK, Until Now Incyte has something to be thankful for this week. Novartis is giving the company a wad of cash to license its most promising drug candidate for myelofibrosis |
The Motley Fool
June 13, 2008
Brian Orelli |
Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
December 22, 2009
Brian Orelli |
Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
January 7, 2009
Brian Orelli |
A One-Hit Wonder Goes for No. 2 Onyx Pharmaceuticals announces its second license in the last few months. |
The Motley Fool
May 15, 2007
Mike Havrilla |
A Tale of Two Trials at YM Bio Encouraging results and ongoing drug trials give YM BioSciences' investors hope. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 17, 2011
Brian Orelli |
In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
The Motley Fool
December 11, 2008
Brian Orelli |
ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool
July 1, 2011
Alex Crawford |
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval? |
The Motley Fool
October 1, 2009
Brian Orelli |
Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock. |
The Motley Fool
December 13, 2011
David Williamson |
3 Biotechs Making Big Moves on Big News Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
Chemistry World
December 20, 2012
Andrew Turley |
Gilead buys YM for $510m US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
Chemistry World
August 28, 2012
Andrew Turley |
Myelofibrosis drug approved in EU Jakavi (ruxolitinib) tablets have been approved in the EU for the treatment of myelofibrosis, a rare disease affecting the bone marrow. |
The Motley Fool
July 21, 2011 |
Avoid This Biotech Stock Our investing community's latest stock to avoid: Infinity Pharmaceuticals. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Rheumatoid Arthritis: JAKing Down Inflammation In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis, Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte. |
The Motley Fool
August 23, 2005
W.D. Crotty |
A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look? |
The Motley Fool
October 26, 2010
Selena Maranjian |
Make Money in Biotech the Simple Way These ETFs present an easy way to invest in biotechnology. |
The Motley Fool
November 28, 2009
Rick Aristotle Munarriz |
A Fool Looks Back Novartis and News Corp were in the news this week for exploring and making deals. Retailers also were in the spotlight. |
